Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ANAB

ANAB - AnaptysBio Inc Stock Price, Fair Value and News

$64.93+1.14 (+1.79%)
Market Closed

62/100

ANAB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

62/100

ANAB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ANAB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANAB Price Action

Last 7 days

17.2%

Last 30 days

17.5%

Last 90 days

44.5%

Trailing 12 Months

285.6%

ANAB RSI Chart

ANAB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANAB Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-141.07

Price/Sales (Trailing)

7.96

EV/EBITDA

24.13

Price/Free Cashflow

95.19

ANAB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ANAB Fundamentals

ANAB Revenue

Revenue (TTM)

234.6M

Rev. Growth (Yr)

151.08%

Rev. Growth (Qtr)

41.84%

ANAB Earnings

Earnings (TTM)

-13.2M

Earnings Growth (Yr)

327.75%

Earnings Growth (Qtr)

228.29%

ANAB Profitability

EBT Margin

-5.57%

Return on Equity

-35.56%

Return on Assets

-3.63%

Free Cashflow Yield

1.05%

ANAB Investor Care

Buy Backs (1Y)

6.26%

Diluted EPS (TTM)

-0.43

ANAB Alerts

  • 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025111.9M123.2M169.5M234.6M
202423.0M30.5M57.2M91.3M
202311.3M13.7M14.7M17.2M
202250.0M36.7M23.5M10.3M
202171.2M101.3M122.2M63.2M
202023.0M18.0M18.0M75.0M
201907.5M10.0M8.0M
2018003.3M5.0M
2017018.8M13.0M1.6M
201617.3M17.1M16.9M16.7M
201500017.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About AnaptysBio Inc

ANAB
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
 CEO
 WEBSITEanaptysbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES96

AnaptysBio Inc Frequently Asked Questions

ANAB is the stock ticker symbol of AnaptysBio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of AnaptysBio Inc is 1.87 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, ANAB's PE ratio (Price to Earnings) is -141.07 and Price to Sales (PS) ratio is 7.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANAB PE ratio will change depending on the future growth rate expectations of investors.